But no difference in disability progression seen for high-efficacy versus low-efficacy therapy for secondary progressive multiple sclerosis
TUESDAY, July 13, 2021 (HealthDay News) — High-efficacy disease-modifying therapies may reduce flare-ups in recently active secondary progressive multiple sclerosis (SPMS), but they do not appear to offer any advantage over low-efficacy therapies for slowing disability progression, according to a study published online June 30 in Neurology.
Izanne Roos, M.B.Ch.B., from the University of Melbourne in Australia, and colleagues compared the clinical effectiveness of high-efficacy treatments (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, and fingolimod) and low-efficacy treatments (interferon β, glatiramer acetate, and teriflunomide) in 1,000 patients with recently active and inactive SPMS followed for 10 years.
The researchers found that patients with active SPMS treated with high-efficacy therapy experienced less frequent relapses than those on low-efficacy therapy (hazard ratio, 0.7; 95 percent confidence interval, 0.5 to 0.9; P = 0.006). However, the investigators found no evidence for a difference in relapse frequency between groups (hazard ratio, 0.8; 95 percent confidence interval, 0.6 to 1.2; P = 0.39) among patients with inactive SPMS. There was also no evidence found for a difference in the risk for disability progression for both active and inactive SPMS (hazard ratios [95 percent confidence intervals], 1.1 [0.8 to 1.5] and 1.3 [0.9 to 1.8], respectively).
“When the goal is to alleviate ongoing relapse activity, more potent therapy is justified,” a coauthor said in a statement. “But when the goal is to limit disability progression in secondary progressive MS, both types of drugs show comparable effectiveness.”
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Occupational Exposure to Petroleum Linked to Increased Risk for MS
CDC: 1 in 10 U.S. Adults Reported GLP-1 Medication Use July to August 2025
β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in RA
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions